{
  "items": "22",
  "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
  "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
  "feed": [
    {
      "title": "Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for Sil204 in Locally Advanced Pancreatic Cancer",
      "url": "https://www.marketscreener.com/news/silexion-therapeutics-announces-submission-of-phase-2-3-clinical-trial-application-to-israel-for-sil-ce7d50dcda8ef62d",
      "time_published": "20251216T140919",
      "authors": [
        "NULL"
      ],
      "summary": "Silexion Therapeutics has submitted a regulatory application in Israel for its planned Phase 2/3 clinical trial of SIL204 for patients with locally advanced pancreatic cancer. This submission is a significant step towards initiating human trials, planned for the second quarter of 2026, and is supported by positive feedback from the German health authority and recent toxicology studies. Silexion also intends to file regulatory applications in Germany and the European Union in early 2026, with U.S. clinical sites to follow.",
      "banner_image": "NULL",
      "source": "www.marketscreener.com",
      "category_within_source": "General",
      "source_domain": "www.marketscreener.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.908335"
        }
      ],
      "overall_sentiment_score": 0.446053,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SLXN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.443388",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Silexion Therapeutics Submits Phase 2/3 Trial Application for SIL204",
      "url": "https://www.tradingview.com/news/tradingview:2641fcfbff0bf:0-silexion-therapeutics-submits-phase-2-3-trial-application-for-sil204/",
      "time_published": "20251216T140901",
      "authors": [
        "NULL"
      ],
      "summary": "Silexion Therapeutics announced on December 16, 2025, the submission of a Phase 2/3 clinical trial application in Israel for SIL204, marking a significant step toward trial initiation in Q2 2026. This follows successful toxicology studies and positive regulatory feedback from Germany, with further filings planned for Germany and the EU in Q1 2026, and U.S. expansion expected post-safety run-in.",
      "banner_image": "NULL",
      "source": "TradingView \u2014 Track All Markets",
      "category_within_source": "General",
      "source_domain": "TradingView \u2014 Track All Markets",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.922484"
        }
      ],
      "overall_sentiment_score": 0.415104,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SLXN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.437396",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer",
      "url": "https://www.globenewswire.com/news-release/2025/12/16/3206243/0/en/Silexion-Therapeutics-Announces-Submission-of-Phase-2-3-Clinical-Trial-Application-to-Israel-for-SIL204-in-Locally-Advanced-Pancreatic-Cancer.html",
      "time_published": "20251216T140901",
      "authors": [],
      "summary": "Silexion Therapeutics has submitted a regulatory application in Israel for its planned Phase 2/3 clinical trial of SIL204 for locally advanced pancreatic cancer, aiming for trial initiation in Q2 2026. This submission follows positive feedback from German authorities, successful toxicology studies, and strong preclinical data showing significant cancer cell inhibition. The company plans further regulatory filings in Germany and the EU in Q1 2026, with U.S. expansion after safety run-in completion.",
      "banner_image": "https://ml-eu.globenewswire.com/media/NzUxMjA1OTctZTQzNy00NGQ3LWFiMmMtNWQxNTIzYTNhN2M5LTEzMDgyMjItMjAyNS0xMi0xNi1lbg==/tiny/Silexion-Therapeutics-Corp.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.42825,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SLXN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.425394",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Silexion Therapeutics Advances Regulatory Submission for Phase 2/3 Trial of SIL204 in Pancreatic Cancer",
      "url": "https://www.quiverquant.com/news/Silexion+Therapeutics+Advances+Regulatory+Submission+for+Phase+2%2F3+Trial+of+SIL204+in+Pancreatic+Cancer",
      "time_published": "20251216T135100",
      "authors": [
        "NULL"
      ],
      "summary": "Silexion Therapeutics has submitted a regulatory application in Israel to advance its Phase 2/3 clinical trial for SIL204, an RNA-based therapy targeting locally advanced pancreatic cancer. The company aims to initiate human trials in Q2 2026, following positive toxicology studies and preclinical data showing significant cancer cell inhibition. This move marks a pivotal step for Silexion in addressing the critical unmet medical need in pancreatic cancer.",
      "banner_image": "NULL",
      "source": "Quiver Quantitative",
      "category_within_source": "General",
      "source_domain": "Quiver Quantitative",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.925357"
        }
      ],
      "overall_sentiment_score": 0.478521,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SLXN",
          "relevance_score": "0.975848",
          "ticker_sentiment_score": "0.482514",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer",
      "url": "https://www.globenewswire.com/news-release/2025/12/16/3206243/0/en/silexion-therapeutics-announces-submission-of-phase-2-3-clinical-trial-application-to-israel-for-sil204-in-locally-advanced-pancreatic-cancer.html",
      "time_published": "20251216T084000",
      "authors": [
        "NULL"
      ],
      "summary": "Silexion Therapeutics has submitted a regulatory application in Israel for its Phase 2/3 clinical trial of SIL204 for locally advanced pancreatic cancer, following positive feedback from German authorities and successful toxicology studies. This marks a significant step towards initiating human trials in Q2 2026, with further regulatory filings planned for Germany and the EU in Q1 2026. SIL204 is designed to silence mutated KRAS oncogenes, a common driver in human cancers.",
      "banner_image": "https://ml-eu.globenewswire.com/media/NzUxMjA1OTctZTQzNy00NGQ3LWFiMmMtNWQxNTIzYTNhN2M5LTEzMDgyMjItMjAyNS0xMi0xNi1lbg==/tiny/Silexion-Therapeutics-Corp.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.929900"
        },
        {
          "topic": "finance",
          "relevance_score": "0.613165"
        }
      ],
      "overall_sentiment_score": 0.407324,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SLXN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.414077",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Silexion Shares Decline After Update on German Regulatory Review",
      "url": "https://www.msn.com/en-us/money/markets/silexion-shares-decline-after-update-on-german-regulatory-review/ar-AA1RzgXt?ocid=finance-verthp-feeds",
      "time_published": "20251207T044409",
      "authors": [],
      "summary": "This article mentions that Silexion shares have declined following an update regarding a German regulatory review. However, the provided content is incomplete and does not offer any further details about Silexion, the regulatory review, or the extent of the share decline.",
      "banner_image": null,
      "source": "MSN",
      "category_within_source": "General",
      "source_domain": "MSN",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.835127"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.745333"
        }
      ],
      "overall_sentiment_score": -0.440292,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "SLXN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.418433",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer",
      "url": "https://www.globenewswire.com/news-release/2025/12/02/3197820/0/en/Silexion-Therapeutics-Receives-Positive-Feedback-from-German-Health-Authority-on-Design-of-Phase-2-3-Clinical-Trial-in-Pancreatic-Cancer.html",
      "time_published": "20251202T080000",
      "authors": [],
      "summary": "Silexion Therapeutics announced positive feedback from the German Federal Institute for Drugs and Medical Devices (BfArM) regarding the design of its planned Phase 2/3 clinical trial for SIL204, its lead product candidate for locally advanced pancreatic cancer. This feedback provides regulatory clarity and reinforces the company's trajectory toward a Q2 2026 trial initiation. Silexion plans to complete regulatory submissions in Israel by Q4 2025 and in Germany during Q1 2026.",
      "banner_image": "https://ml-eu.globenewswire.com/media/YTI2MTVjZjQtMmZmYS00Njk5LWE0Y2QtMGI5MDMxZGZiMjYwLTEzMDgyMjItMjAyNS0xMi0wMi1lbg==/tiny/Silexion-Therapeutics-Corp.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.405485,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SLXN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.412111",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Silexion (NASDAQ: SLXN) gains BfArM Scientific Advice, targets H1 2026 Phase 2/3 start",
      "url": "https://www.stocktitan.net/news/SLXN/silexion-therapeutics-receives-positive-feedback-from-german-health-9cbtq23liimw.html",
      "time_published": "20251202T080000",
      "authors": [
        "NULL"
      ],
      "summary": "Silexion Therapeutics (NASDAQ: SLXN) has received formal written Scientific Advice from the German Federal Institute for Drugs and Medical Devices (BfArM) regarding its planned Phase 2/3 trial design for SIL204 in pancreatic cancer. This feedback confirmed the acceptability of core elements like clinical design, dosing, and patient population, significantly clarifying the regulatory path. The company plans regulatory submissions in Israel by end-Q4 2025 and Germany in Q1 2026, aiming to initiate the Phase 2/3 trial in H1 2026.",
      "banner_image": "https://www.globenewswire.com/newsroom/ti?nf=MTAwMTE0MjI1MiM0MDIyNzUyNzkjMjI5NjY3Mg==",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.919600"
        }
      ],
      "overall_sentiment_score": 0.421249,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SLXN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.404524",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer",
      "url": "https://www.abc4.com/business/press-releases/globenewswire/1001142252/silexion-therapeutics-receives-positive-feedback-from-german-health-authority-on-design-of-phase-2-3-clinical-trial-in-pancreatic-cancer",
      "time_published": "20251202T080000",
      "authors": [
        "NULL"
      ],
      "summary": "Silexion Therapeutics has received positive Scientific Advice from the German Federal Institute for Drugs and Medical Devices (BfArM) regarding the design of its planned Phase 2/3 clinical trial for SIL204 in locally advanced pancreatic cancer. This feedback provides significant regulatory clarity, reinforcing the company's trajectory towards initiating the trial in Q2 2026. Silexion plans to complete regulatory submissions in Israel by the end of Q4 2025 and in Germany during Q1 2026.",
      "banner_image": "https://ml-eu.globenewswire.com/media/YTI2MTVjZjQtMmZmYS00Njk5LWE0Y2QtMGI5MDMxZGZiMjYwLTEzMDgyMjItMjAyNS0xMi0wMi1lbg==/tiny/Silexion-Therapeutics-Corp.png",
      "source": "ABC4 Utah",
      "category_within_source": "General",
      "source_domain": "ABC4 Utah",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.921580"
        }
      ],
      "overall_sentiment_score": 0.403895,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SLXN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.421115",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer",
      "url": "https://www.sahmcapital.com/news/content/silexion-therapeutics-receives-positive-feedback-from-german-health-authority-on-design-of-phase-23-clinical-trial-in-pancreatic-cancer-2025-12-02",
      "time_published": "20251201T150929",
      "authors": [
        "NULL"
      ],
      "summary": "Silexion Therapeutics has received positive Scientific Advice from the German Federal Institute for Drugs and Medical Devices (BfArM) regarding its proposed Phase 2/3 clinical trial design for SIL204, a lead product candidate for pancreatic cancer. This feedback provides significant regulatory clarity, reinforcing the company's plan to initiate the trial in Q2 2026. The company anticipates completing regulatory submissions in Israel by the end of Q4 2025 and in Germany during Q1 2026.",
      "banner_image": "NULL",
      "source": "Sahm",
      "category_within_source": "General",
      "source_domain": "Sahm",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.941449"
        }
      ],
      "overall_sentiment_score": 0.422118,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SLXN",
          "relevance_score": "0.987133",
          "ticker_sentiment_score": "0.416623",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "SLXN - Silexion Therapeutics Corp Latest Stock News & Market Updates",
      "url": "https://www.stocktitan.net/news/SLXN/page-4.html",
      "time_published": "20251201T044409",
      "authors": [
        "NULL"
      ],
      "summary": "Silexion Therapeutics (NASDAQ: SLXN) is a clinical-stage biotechnology company focused on RNA interference therapies for KRAS-driven cancers, particularly pancreatic cancer. This page aggregates the latest news including preclinical data for SIL-204 showing synergy with chemotherapies, upcoming presentations at major conferences, collaborations with industry leaders like Evonik, executive appointments, and past clinical trial results for LODER\u2122. The company aims to advance SIL-204 into Phase 2/3 clinical trials by 2026.",
      "banner_image": "NULL",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.939836"
        }
      ],
      "overall_sentiment_score": 0.349166,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SLXN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.309059",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.564987",
          "ticker_sentiment_score": "0.313896",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.564870",
          "ticker_sentiment_score": "0.322896",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer",
      "url": "https://www.sahmcapital.com/news/content/silexion-therapeutics-successfully-completes-toxicology-studies-for-sil204-next-generation-rna-silencing-therapy-ahead-of-phase-23-clinical-trial-in-pancreatic-cancer-2025-11-25",
      "time_published": "20251128T160855",
      "authors": [],
      "summary": "Silexion Therapeutics announced the successful completion of toxicology studies for SIL204, its next-generation RNA silencing therapy for KRAS-driven cancers. These studies confirmed no systemic organ toxicity, clearing the path for planned regulatory submissions in Israel and Germany. The company remains on track to initiate a Phase 2/3 clinical trial in locally advanced pancreatic cancer in Q2 2026.",
      "banner_image": null,
      "source": "Sahm",
      "category_within_source": "General",
      "source_domain": "Sahm",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.038679,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "SLXN",
          "relevance_score": "0.302921",
          "ticker_sentiment_score": "0.010451",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference",
      "url": "https://www.globenewswire.com/news-release/2025/11/26/3195059/0/en/Silexion-Therapeutics-to-Present-at-Noble-Capital-Markets-21st-Annual-Emerging-Growth-Equity-Conference.html",
      "time_published": "20251126T073000",
      "authors": [
        "NULL"
      ],
      "summary": "Silexion Therapeutics will present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference (NobleCon21) on December 3, 2025. CEO Ilan Hadar and CFO Mirit Horenshtein-Hadar will speak from 2:30 \u2013 2:55 pm ET at Florida Atlantic University Conference Center. The company, focused on oncology treatments for KRAS oncogene-mutated solid tumors, will also be available for one-on-one meetings.",
      "banner_image": "https://ml-eu.globenewswire.com/media/OWFkNTExMjUtN2UyYy00NmM1LWE5MjctMGI3Zjc2NGZjYTRmLTEzMDgyMjItMjAyNS0xMS0yNi1lbg==/tiny/Silexion-Therapeutics-Corp.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "finance",
          "relevance_score": "0.749222"
        }
      ],
      "overall_sentiment_score": 0.159567,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SLXN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.290102",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NDAQ",
          "relevance_score": "0.608542",
          "ticker_sentiment_score": "0.032229",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer",
      "url": "https://finance.yahoo.com/news/silexion-therapeutics-successfully-completes-toxicology-141500526.html",
      "time_published": "20251125T150901",
      "authors": [
        "NULL"
      ],
      "summary": "Silexion Therapeutics has successfully completed toxicology studies for SIL204, a next-generation RNA silencing therapy targeting mutated KRAS oncogenes, confirming no systemic organ toxicity. This milestone advances the company towards initiating a Phase 2/3 clinical trial in locally advanced pancreatic cancer in Q2 2026. The preclinical data for SIL204 demonstrated significant inhibition of cancer cell growth, and the company plans regulatory submissions to Israel and Germany.",
      "banner_image": "https://s.yimg.com/ny/api/res/1.2/rj0Ta3GGeVAy26gXI.Thag--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIyNDtoPTQ4O2cfPXdlYnA-/https://s.yimg.com/os/creatr-uploaded-images/2025-08/b2b7bbc0-8385-11f0-977e-d9d7d4cd04d2",
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.421533,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SLXN",
          "relevance_score": "0.972884",
          "ticker_sentiment_score": "0.438489",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Silexion Therapeutics Reports Successful Toxicology Study Results for SIL204, Paving the Way for Upcoming Phase 2/3 Clinical Trial in Pancreatic Cancer",
      "url": "https://www.quiverquant.com/news/Silexion+Therapeutics+Reports+Successful+Toxicology+Study+Results+for+SIL204%2C+Paving+the+Way+for+Upcoming+Phase+2%2F3+Clinical+Trial+in+Pancreatic+Cancer",
      "time_published": "20251125T142200",
      "authors": [
        "NULL"
      ],
      "summary": "Silexion Therapeutics has announced the successful completion of toxicology studies for its RNA interference therapy, SIL204, confirming no systemic organ toxicity. This milestone paves the way for regulatory submissions in Israel and Germany and the initiation of a Phase 2/3 clinical trial for locally advanced pancreatic cancer by Q2 2026. The company's CEO expressed confidence in SIL204's potential to improve patient outcomes, building on positive preclinical data showing significant anti-tumor activity.",
      "banner_image": "https://www.quiverquant.com/images/slxn_rect_new.png",
      "source": "Quiver Quantitative",
      "category_within_source": "General",
      "source_domain": "Quiver Quantitative",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.489896,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SLXN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.467930",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Silexion stock jumps after toxicology studies show no systemic toxicity",
      "url": "https://www.investing.com/news/stock-market-news/silexion-stock-jumps-after-toxicology-studies-show-no-systemic-toxicity-93CH-4377775",
      "time_published": "20251125T105200",
      "authors": [
        "Investing.com"
      ],
      "summary": "Silexion Therapeutics Corp (NASDAQ:SLXN) stock rose 5.9% after announcing the successful completion of toxicology studies for its cancer therapy, SIL204. These studies confirmed no systemic organ toxicity in two species, allowing the company to proceed with a Phase 2/3 clinical trial for locally advanced pancreatic cancer in Q2 2026. Silexion is now preparing regulatory submissions for health authorities in Israel and Germany.",
      "banner_image": "https://i-invdn-com.investing.com/news/LYNXMPEC0409P_L.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.925669"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.806780"
        }
      ],
      "overall_sentiment_score": 0.818214,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SLXN",
          "relevance_score": "0.904274",
          "ticker_sentiment_score": "0.806756",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Silexion Therapeutics Corp Announces Drop In Q3 Bottom Line",
      "url": "https://www.rttnews.com/3594391/silexion-therapeutics-corp-announces-drop-in-q3-bottom-line.aspx",
      "time_published": "20251112T090900",
      "authors": [
        "RTTNews Staff Writer"
      ],
      "summary": "Silexion Therapeutics Corp (SLXN) reported a significant drop in its third-quarter profit, totaling $3.26 million, or $2.88 per share. This is a substantial decrease compared to $11.86 million, or $274.25 per share, in the same period last year. The company's bottom line has decreased considerably on a year-over-year basis.",
      "banner_image": null,
      "source": "RTTNews",
      "category_within_source": "General",
      "source_domain": "RTTNews",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.807376"
        }
      ],
      "overall_sentiment_score": -0.404051,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "SLXN",
          "relevance_score": "0.971594",
          "ticker_sentiment_score": "-0.409174",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update",
      "url": "https://www.globenewswire.com/news-release/2025/11/12/3186310/0/en/Silexion-Therapeutics-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Update.html",
      "time_published": "20251112T090000",
      "authors": [],
      "summary": "Silexion Therapeutics (NASDAQ: SLXN) announced its Q3 2025 financial results, highlighting significant progress towards initiating Phase 2/3 clinical trials for SIL204 in the first half of 2026. The company reported strong preclinical data for SIL204 against multiple KRAS-driven cancer types and successfully raised over $9 million, strengthening its balance sheet and regaining Nasdaq listing compliance. Financial results showed a reduced net loss compared to the previous year, driven by lower R&D and G&A expenses.",
      "banner_image": "https://ml-eu.globenewswire.com/media/M2E2NmVmNDEtOThkZS00ZDI3LTk1NTQtODc4MGYxODBiM2FkLTEzMDgyMjItMjAyNS0xMS0xMi1lbg==/tiny/Silexion-Therapeutics-Corp.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.939674"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.825499"
        },
        {
          "topic": "finance",
          "relevance_score": "0.625876"
        }
      ],
      "overall_sentiment_score": 0.487301,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SLXN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.458265",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer",
      "url": "https://www.globenewswire.com/news-release/2025/09/30/3158625/0/en/Silexion-Therapeutics-Announces-Positive-New-Human-Cell-Line-Data-Confirming-Pan-KRAS-Activity-of-SIL204-Demonstrating-Up-to-99-7-Inhibition-and-First-Evidence-in-Gastric-Cancer.html",
      "time_published": "20250930T084000",
      "authors": [],
      "summary": "Silexion Therapeutics Corp. announced positive new human cell line data showing that its RNAi therapy, SIL204, exhibits pan-KRAS activity, achieving up to 99.7% inhibition across various KRAS mutations in multiple cancer types. The data confirms SIL204's potential as a comprehensive therapeutic for KRAS-driven cancers, including new evidence in gastric cancer and expanded validation in colorectal cancer. The company plans to advance SIL204 towards Phase 2/3 clinical trials with regulatory submissions expected in late 2025 and early 2026.",
      "banner_image": "https://ml-eu.globenewswire.com/media/M2ZjODBhZjctY2JhZS00OWQwLWE5ZmMtYWFkYjQ2YmM3ZDRlLTEzMDgyMjItMjAyNS0wOS0zMC1lbg==/tiny/Silexion-Therapeutics-Corp.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.928346"
        }
      ],
      "overall_sentiment_score": 0.364648,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SLXN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.884815",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.568260",
          "ticker_sentiment_score": "0.267964",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.559686",
          "ticker_sentiment_score": "0.214439",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.557067",
          "ticker_sentiment_score": "0.257184",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "LLY",
          "relevance_score": "0.596968",
          "ticker_sentiment_score": "0.289347",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Silexion stock soars 400% after positive pancreatic cancer drug data",
      "url": "https://www.investing.com/news/stock-market-news/silexion-stock-soars-400-after-positive-pancreatic-cancer-drug-data-93CH-4235184",
      "time_published": "20250911T070800",
      "authors": [
        "Investing.com"
      ],
      "summary": "Silexion Therapeutics Corp.'s stock surged 400% after reporting positive preclinical data for its pancreatic cancer drug, SIL204. The drug demonstrated significant anti-tumor activity in a mouse model, reaching all major metastatic sites after subcutaneous administration. The company plans to initiate Phase 2/3 clinical trials in early 2026, with regulatory submissions expected in late 2025 and early 2026.",
      "banner_image": "https://i-invdn-com.investing.com/news/LYNXMPEA7H0NX_L.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.949736"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.731937"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.612753"
        }
      ],
      "overall_sentiment_score": 0.854735,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SLXN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.879335",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference",
      "url": "https://finance.yahoo.com/news/silexion-therapeutics-present-upcoming-27th-124500681.html",
      "time_published": "20250902T044409",
      "authors": [
        "NULL"
      ],
      "summary": "Silexion Therapeutics (NASDAQ: SLXN), a clinical-stage biotechnology company, announced its senior management will present at the 27th Annual H.C. Wainwright Global Investment Conference from September 8-10, 2025, in New York City. The presentation will occur on September 10, 2025, at 2:00 PM ET, and updated company information is available on their investor website. Management will also be available for one-on-one investor meetings at the event.",
      "banner_image": "https://s.yimg.com/ny/api/res/1.2/rj0Ta3GGeVAy26gXI.Thag--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIyNDtoPTQ4O2NmPXdlYnA-/https://s.yimg.com/os/creatr-uploaded-images/2025-08/b2b7bbc0-8385-11f0-977e-d9d7d4cd04d2",
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.945928"
        },
        {
          "topic": "finance",
          "relevance_score": "0.743494"
        }
      ],
      "overall_sentiment_score": 0.272675,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SLXN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.269620",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Silexion Therapeutics stock falls after warrant exercise deal",
      "url": "https://www.investing.com/news/stock-market-news/silexion-therapeutics-stock-falls-after-warrant-exercise-deal-93CH-4165997",
      "time_published": "20250801T130834",
      "authors": [
        "Investing.com Investing.com"
      ],
      "summary": "Silexion Therapeutics Corp (NASDAQ: SLXN) stock fell 22.4% in pre-market trading after the company announced definitive agreements for the immediate exercise of certain outstanding warrants. This deal, involving the exercise of warrants for up to 152,106 ordinary shares at a reduced price, is expected to generate approximately $1.8 million for Silexion, which develops RNA interference therapies for KRAS-driven cancers. Additionally, new unregistered warrants for up to 304,212 ordinary shares will be issued, exercisable upon shareholder approval to increase authorized shares.",
      "banner_image": "https://i-invdn-com.investing.com/news/LYNXNPEB9606Q_L.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.924266"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.848834"
        }
      ],
      "overall_sentiment_score": -0.464273,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "SLXN",
          "relevance_score": "0.959039",
          "ticker_sentiment_score": "-0.458606",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    }
  ]
}